(1S)-4,5-Dimethoxy-1-(Methylaminomethyl)-Benzocyclobutane Hydrochloride

DRUG INTERMEDIATES

Product Details

CAT No.# CS-O-32291
Category Drug Intermediates
CAS 866783-13-3
Molecular Weight 243.73
Stock Status: In-Stock
Purity: >98%
Melting Point: >216
Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
Appearance: White Solid
Synonyms: Ivabradine Impurity 17;(7S)-3,4-Dimethoxy-N-methyl-bicyclo[4.2.0]octa-1,3,5-triene-7-methanamine Hydrochloride;
References: Thollon,C., et al.: Br. J. Pharmacol., 112, 37 (1994), Ragueneau, I., et al.: Clin. Pharmacol. Ther., 64, 192 (1998), Borer, J.S., et al.: Circulation, 107, 817 (2003), DiFrancesco, D., et al.: Drugs, 64, 1757 (2004)
Shipping: Free Shipping for worldwide on order above 2000 USD , Extra charges for Dry ice shipment 80$*
COA / MSDS:    View COA    MSDS
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
Related Results for '(1S)-4,5-Dimethoxy-1-(Methylaminomethyl)-Benzocyclobutane Hydrochloride'

- API Standards of Ivabradin
- Stable Isotopes of Ivabradin
- Metabolites of Ivabradin
- Impurities of Ivabradin
- Glucuronides of Ivabradin
- Intermediates of Ivabradin

PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Benidipine D7
4. Lauroside D
5. Triazolam 13C D3
6. Icatibant impurity 1
7. BISPHENOL AF (RING-13C12)
8. 0.1% TFA in Water ULC-MS
9. Metamizole EP Impurity C HCl
10. Silodosin Metabolite D4
11. Brivaracetam Carboxylic acid metabolite [UCB 42145]
12. Terbuthylazine D5
13. tibolone (848)
14. (Z)-Dimethylvinphos
15. Silodosin Metabolite
16. 2-Phenoxymethanesulfonanilide
17. Nimesulide EP Impurity A
18. Acetone HPLC
19. Nandrolone Decanoate EP impurity F
20. N-(4-Bromophenyl)-3-methyl-N-(m-tolyl)aniline


Smileys:
CNC[C@@H]1C2=CC(OC)=C(OC)C=C2C1.Cl



This page contains information about (1S)-4,5-Dimethoxy-1-(Methylaminomethyl)-Benzocyclobutane Hydrochloride Cas 866783-13-3 and its Drug Intermediates.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."